Based on the results of IMpower150, ACPB regimen was approved by the U.S. FDA in 2018 for the first‐line treatment of advanced nonsquamous NSCLC with no EGFR or ALK genomic tumor aberrations. The gene discussed is ALK; the disease is non-small cell lung carcinoma.